Angiopoietins differentially influence in vitro angiogenesis by endothelial cells of different origin

Angiopoietins are important growth factors for vascular development and quiescence. They are promising targets for pro-or anti-angiogenic therapies in diverse pathologies, but the mechanisms of the ANGPT/TIE2 system are complex and not well understood. In the present study, the separate and combined effects of angiopoietin 1 and angiopoietin 2 were studied, using a recently developed in vitro angiogenesis model that allows both a quantitative and qualitative evaluation of the angiogenic cascade. This cell culture model was performed with microvascular endothelial cells (ECs) originating from different vascular beds, i.e. dermal ECs and cardiac ECs. In addition, the expression of the angiopoietins and the receptors, TIE1 and TIE2 was analyzed with RT-qPCR. This study revealed that the angiopoietins provoked a differential response in the two endothelial cultures. Both angiopoietin 1 as well as angiopoietin 2 elicited an angiogenic cascade in the dermal ECs but not in the cardiac ECs. In addition, the RT-qPCR data revealed marked differences in the endogenous expression pattern of these factors, indicating that the origin of endothelial cells might have an important impact on their angiogenic potential

The use of HIV-1 integration site analysis information in clinical studies aiming at HIV cure

The mechanisms for the establishment and the persistence of the latent HIV-1 reservoir remain to be completely defined. HIV-1 infection is characterised by the integration of the reverse transcribed proviral DNA into the host's genome. This integrated proviral DNA can remain replication silent, but a small part of it is fully competent to restart viral replication when treatment is interrupted. Hence, this replication-competent provirus is the cause of viral rebound and is called the viral reservoir. The exact site of proviral integration within the host` s cellular chromosome may affect the transcriptional activity of HIV. Thanks to recent technological advances, HIV-1 integration site analysis has been used to assess HIV-1 reservoirs in HIV-infected individuals. Analysis of HIV-1 integration sites in infected individuals undergoing suppressive ART led to identification of expanded clonal cell populations, indicating that clonal proliferation of the proviral reservoir may contribute to the long-term persistence of viral reservoirs. Here we describe the findings of several clinical studies, where a comprehensive HIV-1 integration site analysis was performed

Characterization of serotonin transporter expression in human T lymphocytes

Serotonin transporter (SERT) expression has been demonstrated in human lymphocytes, including B lymphocytes, NK cells and other immune cells. However, discussion remains on whether human T lymphocytes express SERT. Given the potentially important role of serotonin in lymphocyte activation and proliferation, we investigated SERT expression in purified human T lymphocytes both in resting and activated state. Blood samples were collected from 9 healthy volunteers. PBMCs were isolated using Ficoll density centrifugation and T lymphocytes were further purified with magnetic activated cell sorting. T cells were either processed for mRNA and protein isolation immediately, or activated using anti-CD3/CD28 coated magnetic beads and allowed to proliferate for 72h at 37°C and 5% CO2. SERT mRNA expression was measured using droplet digital PCR to allow for increased sensitivity in comparison with qRT-PCR. SERT protein was detected on western blot. SERT expression was detected both on mRNA and protein level, although expression levels were very low. On mRNA level, SERT was expressed in both resting and activated cells. On the protein level however, only activated cells displayed SERT expression. This observation might point to a ‘translational readiness’ were resting T lymphocytes already produce SERT mRNA, but translation is only induced after activation of the cell

Diagnostic utility of droplet digital PCR for HIV reservoir quantification

Quantitative real-time PCR (qPCR) is implemented in many molecular laboratories worldwide for the quantification of viral nucleic acids. However, over the last two decades, there has been renewed interest in the concept of digital PCR (dPCR) as this platform offers direct quantification without the need for standard curves, a simplified workflow and the possibility to extend the current detection limit. These benefits are of great interest in terms of the quantification of low viral levels in HIV reservoir research because changes in the dynamics of residual HIV reservoirs will be important to monitor HIV cure efforts. Here, we have implemented a systematic literature screening and text mining approach to map the use of droplet dPCR (ddPCR) in the context of HIV quantification. In addition, several technical aspects of ddPCR were compared with qPCR: accuracy, sensitivity, precision and reproducibility, to determine its diagnostic utility. We have observed that ddPCR was used in different body compartments in multiple HIV-1 and HIV-2 assays, with the majority of reported assays focusing on HIV-1 DNA-based applications (i.e. total HIV DNA). Furthermore, ddPCR showed a higher accuracy, precision and reproducibility, but similar sensitivity when compared to qPCR due to reported false positive droplets in the negative template controls with a need for standardised data analysis (i.e. threshold determination). In the context of a low level of detection and HIV reservoir diagnostics, ddPCR can offer a valid alternative to qPCR-based assays but before this platform can be clinically accredited, some remaining issues need to be resolved

HIV reservoir characterization symposium 19 September 2016, Ghent, Belgium

The HIV Cure Research Center (HCRC) in Ghent organised the first HIV Reservoir Characterization Symposium, and brought together virologists, molecular biologists, immunologists and clinicians to discuss the most recent developments in HIV reservoir characterisation with a view to achieving an HIV cure. The one-day symposium covered new developments in the field of HIV reservoir and HIV cure research, with the latest news on the European HIV cure trials. This report summarises the major themes discussed during the symposium